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Summary Alkylating agents can cause latent and permanent damage to the bone marrow. We compared the
long term effects of melphalan on a number of immune and haemopoietic functions of plasmacytoma bearing
BALB/c mice with that of normal mice treated with a similar dose of melphalan. The drug administered
orally at a dose of 250,ug and 400 pg on day 14 and 24 following i.m. inoculation of MOPC-315
plasmacytoma cells resulted in cure of the mice. Their spleen cells showed a permanent impairment of MLR
activity, T-cell number and IL-2 production as well as a mild suppression of NK activity for one year after
cessation of melphalan therapy. The number of B cells was elevated. In contrast, plasmacytoma-free mice
treated with melphalan retained long term normal immune functions, although shortly after melphalan
therapy a temporary suppression was noted. On the other hand, melphalan was responsible for bone marrow
myeloid stem cell damage since the number of myeloid progenitor cell (CFU-GM) colonies was reduced in
both melphalan-treated groups compared to untreated normal controls. Plasmacytoma bearing mice had a
shorter survival. These results demonstrate that some late sequelae of alkylating agents are not due to the
drug alone; shorter survival and T-cell deficiency are related to the previous presence of the tumour.
Chemotherapeutic drugs often cause a temporary decline in
blood cell production. With the increase in number of cancer
patients who survive long periods after successful treatment,
delayed and permanent bone marrow damage is being
increasingly recognized (Harris, 1979; Testa et al., 1985;
Greenberger et al., 1985; Schofield, 1986; Cuzick et al.,
1987). This may manifest clinically as low tolerance to
subsequent chemotherapy (Testa et al., 1985) or as the
development in some patients, after a clinically quiescent
period, of severe marrow dysplasia with peripheral blood
cytopenia which may progress to secondary acute non-
lymphatic leukaemia (Harris, 1979; Levine & Bloomfield,
1987; Koeffler & Rowley, 1985). Mice exposed to alkylating
agents may develop permanent reduction of haemopoietic
stem cell growth and self renewal despite an apparently
normal blood and bone marrow cellularity (Morley et al.,
1975; Botnick et al., 1978; Hays et al., 1982; Fried & Adler,
1985; Xu et al., 1986). Such a latent marrow injury can later
evolve into frank marrow failure or even transformation to
leukaemia (Botnick et al., 1978; Morley & Blake, 1974).
Although late marrow damage is generally attributed to a
mutagenic effect of the drugs on the haemopoietic stem
cell(s) (Koeffler & Rowley, 1985; Sieber & Adamson, 1975),
the role of host factors has not been well studied.
Adaptive or natural immune effector mechanisms could
mediate host surveillance against potentially malignant cells
transformed by chemotherapy (Stutman, 1981). A deficient
or malfunctioning host immune defence could allow the
expansion of transformed, premalignant cells (Stutman,
1981; Nowell, 1986). However in patients cured of cancer by
chemotherapy the analysis of the immune status is difficult
to interpret. Late immune deficiency may not only reflect
damage by the chemotherapeutic drugs, but also a late effect
of the primary disease (Griffin et al., 1982; Milles & Cawley,
1983; Pilarski et al., 1985).
In view of this uncertainty, we studied the long term
effects of melphalan, on immune parameters of BALB/c
mice cured of a transplanted plasmacytoma, in comparison
to the drug's effects on mice without the tumour. Melphalan
and plasmacytoma were chosen since patients with multiple
myeloma are at a high risk for late myelodysplasia and acute
leukaemia (Bergsagel & Pruzanski, 1985; Cuzick et al., 1987).
We focused on the immune profile during a period of one
year after tumour eradication and off therapy. Concomi-
tantly the in vitro growth of marrow myeloid progenitor
cells was determined. This model enabled us to discriminate
between long term damage to the immune and haemopoietic
systems due to melphalan and injury related to the previous
tumour burden.
Materials and methods
Tumour cells
Mineral oil-induced MOPC-315 plasmacytoma, (Potter &
Walters, 1973; Ben-Efraim et al., 1983) was obtained from
Dr S. Ben-Efraim, Tel Aviv University, and maintained in
vivo by serial i.m. inoculations into syngeneic BALB/c mice.
YAC-1 cells were kindly provided by Dr R.B. Herberman
and maintained in culture in RPMI-1640 medium
supplemented with L-glutamine and foetal calf serum (FCS)
(Maagar, Israel).
Chemicals
Melphalan-(L-phenylalanine mustard) (Wellcome Foun-
dation, London, UK) was dissolved in distilled water.
Plasmacytoma bearing mouse model
Intramuscular injection of 103 MOPC-315 plasmacytoma
cells to BALB/c mice on day 0 results in local tumour
formation by day 10, gradually growing in size and causing
death in 100% of the mice by day 50. The dose and time of
melphalan administration were based on preliminary dose
response experiments (data not shown). The mice received
melphalan intragastrically, 250pg and 400jg, on days 14
and 24 respectively, without significant early death from
toxicity. The tumour disappeared and did not recur
throughout the follow-up period of one year.
Experimental design
Three groups of female BALB/c mice aged 6-8 weeks were
studied: (1) Untreated controls (group C); (2) Plasmacytoma
bearing mice treated with melphalan (group T+M); (3)
Normal mice not inoculated with plasmacytoma cells, but
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treated by the same schedule of melphalan as group T+M
(Group M). The mortality rates, at day 50, of melphalan
treated mouse groups was similar: 6% for group M and
14% for group T+M.
For each experimental group -240 mice were used. They
were followed for a period of 12 months. At monthly
intervals, 15-24 mice which appeared to be well, were killed
randomly from each group and spleen and femur bone
marrow cells were obtained. The immune profile and in vitro
myeloid colony growth were studied. For the final analysis
all values of individual mice at each point in time were
pooled and the mean calculated. The significance of the
differences between the groups was tested by the Student's t
test. All mice were dissected and found free of tumour.
Antibodies
FITC-conjugated monoclonal anti Thy-1.2 and FITC-
conjugated affinity purified goat anti-rabbit IgG were
obtained from Bio-Yeda, Rehovot, Israel. Rabbit IgG anti
asialo GM1 (Wako Pure Chemical Industries, Osaka, Japan)
was absorbed twice with mouse thymocytes (0.5mg of IgG
with 106 cells) before use. FITC-conjugated antisurface Ig
antibodies directed against mu and kappa chains were
provided by Dr Y. Haimovitz, Tel Aviv University, Tel
Aviv, Israel.
Immunofluorescence analysis andflow cytometry
Direct immunofluorescence staining of spleen cells was
performed by incubating each antibody with 106 cells at 4°C
for 30min. Titration curves indicated that all cellular
receptor sites were saturated at the chosen dilution of each
antibody level. The cells were washed twice with RPMI-1640
medium containing 10% FCS and resuspended in 1 ml
medium. Binding of asialo GM1 antibody to the cells was
studied by indirect immunofluorescence using a second step
of FITC-conjugated goat anti-rabbit IgG antibodies. The
amount of fluorescent label per cell was measured with a
flow cytometer (Ortho Diagnostic Instruments model 50H)
using the 488 nm line of Argon ion laser at a power of
200mw. Forward light scatter and 900 fluorescence were
simultaneously measured for each cell. Fluorescence histo-
grams of viable lymphocytes were obtained by removing
dead cells and debris using the scatter signal. Mean
fluorescence values and the percentage of cells in various
subgroups were calculated directly using a flow cytometer
computer (model 2150) software. Approximately 105 cells
were analysed for each histogram. Fluorescently labelled
microspheres (1.33,pm diameter, Polysciences) were used as
an internal fluorescence standard and to monitor system
alignment during measurements.
Mixed lymphocyte reaction
Spleen cells were prepared for mixed lymphocytic reaction
(MLR) as previously described (Peck & Bach, 1973). Briefly,
mitogen stimulated cells obtained from C3HeB or BALB/c
mice were incubated with responder cells from the BALB/c
mice at a ratio of 1:1.5 in RPMI-1640 medium and 2.5%
FCS. Three days later the cells were labelled with 3H-
thymidine. The net stimulation was calculated by subtracting
cpm of syngeneic mixed lymphocyte culture from cpm of
allogeneic culture.
cpm in experimental wells -
% lysis= cpm released spontaneously
total cpm incorporated -
cpm released spontaneously
Spontaneous release was 10-30%.
Interleukin-2 (IL-2) production
The IL-2 assay has been described previously (Gillis et al.,
1978). Briefly, spleen cells (8 x I0O cellsml- ) were cultured
with 2.5jpgml-1 of ConA (Bio Yeda, Rehovot, Israel) for
48h. IL-2 production was measured by adding the super-
natants (0.1 ml) to ConA induced blasts (1 x 105cellsml-1)
cultured in RPMI-1640 medium containing 10% FCS, and
5 x 10-5M 2-mercaptoethanol and labelled with 3H-thymidine.
IL-2 units were calculated with the aid of a standard IL-2
preparation.
CFU-GM colony assay
Bone marrow cells, 105 in 1 ml alpha medium (Flow
Laboratories, Irvine, UK), 15% FCS, 0.3% bacto agar and
10% mouse lung conditioned medium as a source of colony
stimulating activity, were placed in 35mm petri dishes. After
incubation in a humidified incubator with 5% CO2 at 37°C
for 7 days, myeloid-macrophage progenitor cell (CFU-GM)
colonies (>20 cells) were scored.
Results
Survival
Late survival of the mouse groups was compared by life
table analysis (Kaplan & Meier, 1957) (Figure 1). During the
follow-up period of one year, the melphalan-treated
plasmacytoma-bearing mice showed a higher mortality rate
than the group of normal mice treated by equivalent doses
of this drug. No evidence of residual plasmacytoma was
found in any dissected mouse of group T+M.
T-cellfunction and number
The ability of splenic cells from M, T+M and C mouse
groups to respond to alloantigens expressed on C3HeB
splenocytes in MLR is depicted in Figure 2. Melphalan
treatment of healthy mice (group M) resulted in a markedly
reduced MLR. However, 120 days after treatment this
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NK cell assay
Effector spleen cells (100p1) suspended in RPMI-1640
medium containing 20% FCS, were added to 50p of 5tCr-
labelled target cells (YAC-1) (at 2 x I05 cellsml-1) in round
bottomed microtiter plates. After incubation at 37°C for 18h
the cells were centrifuged and the radioactivity in the
supernatant of each well determined. Effector to target ratio
was 50:1. Results were expressed as percentage lysis of target
cells according to the formula:
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Figure 1 Survival by life table analysis in melphalan treated
mice. Mice injected with 103 MOPC-315 cells (group T+M, 0)
or normal mice (group M, *) received melphalan on days 14
and 24. T indicates plasmacytoma inoculation. M indicates
melphalan treatment.
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Figure 2 Allogeneic MLR response in melphalan treated
mice (tumour inoculation and melphalan treatment as in
legend to Figure 1). At each time point the MLR was calculated
as the percentage of cpm of untreated mice, indicated by the
horizontal line (group C). The MLR of group C was 10,000-
50,000cpm. (O =group T+M; 0 group M).
activity recovered spontaneously and remained normal
throughout the experiment. In contrast to the spontaneous
recovery in group M, the MLR in group T+M remained
below normal for one year (P<0.05 as compared to group C
or group M).
Splenic T-cell numbers measured by monoclonal anti
Thyl.2 antibodies are shown in Figure 3. In group M,
melphalan reduced the number of Thyl.2 positive cells but
by day 60 they recovered and reached normal levels. In
group T+M, up to day 60 and after day 120, the impaired
T-cell function was associated with a significant reduction of
Thyl.2 positive cells compared to group C and group M
(P<0.05). Only during a short period (days 60-90) could the
reduced MLR in groups M and T+M not be accounted for
by decreased Thyl.2 positive cells. Throughout the entire
study period production of IL-2 by splenic cells of group
T+M was significantly lower than group M and C
(P<0.05) (Figure 4). Though the difference appears rather
small it was consistent at all points in time.
NK cell activity and number
NK activity of splenic cells is shown in Figure 5. A wide
range of levels was found in untreated control mice (group
C). After 210 days of observation NK activity declined,
presumably due to aging of the mice. Melphalan treatment
of normal mice (group M) markedly suppressed NK activity,
recovering to normal after day 90. The NK activity in group
T+M did not decline until day 60 after treatment. During
days 60-240 the NK activity in group T+M was lower than
30 90 180 270 360
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Figure 4 IL-2 production by splenic cells of melphalan treated
mice (see legend to Figure 2). IL-2 production by untreated
control mice was 30-120 units. (O =group T+M; 0 =group
M.)
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Figure 5 NK activity in untreated control (group C, A) and in
melphalan treated mice [groups M(J) and T+M(O)J.
Melphalan treatment and plasmacytoma inoculation as in legend
to Figure 1. Cytotoxicity was calculated at 50:1 effector to target
cell ratio.
in normal untreated mice (P<0.05). In general, the
differences in NK activity between the three mouse groups
were minimal. Figure 6 demonstrates that in both treated
groups (M and T+M) the number of NK (asialo GM1
positive) cells was initially markedly reduced, rollowed by a
spontaneous recovery by -day 80, and no further decline
during the rest of the study period.
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Both melphalan-treated groups (M and T+M) showed an
initial reduction in the number of splenic surface immuno-
globulin (SIg) positive cells, recovering by day 120.
Furthermore, the number of B cells in the T+M group was
significantly higher than in group M or group C (P<0.05)
(Figure 7). The possibility that the higher number of SIg
positive B cells in group T+M were due to residual plasma-
cytoma cells was ruled out, since the MOPC-315 plasma-
cytoma cells express a and A2 chains. Indeed, neither ascites
nor cultured MOPC-315 cells were labelled with our anti Ig
reagent. Furthermore, an i.m. inoculation of as many as
5 x 106 splenic cells from group T+M to syngeneic BALB/c
mice caused neither local nor systemic plasmacytoma while
as few as 103 MOPC-315 cells caused local tumours resulting
-ulation in 100% mortality.
Figure 3 Percentage of splenic T-cells in melphalan treated mice
(see legend to Figure 2). In untreated normal mice, 28-40% of
spleen cells were Thy 1.2+. (O=group T+M; 0=group M.)
Bone marrow CFU-GM growth
By day 110 after melphalan treatment the growth of CFU-
160
-a
120 C
0
° 80
40
-rv zut r r
I I I I I I a-
273
-
"'*Id
k
A ^274 0. SAGI et al.
120
-
(60-120%) -
80 _
40
I I I , I
-a
0
C-)
0
0 30
T MM
90 180 270 360
Days after tumour inoculation
Figure 8 CFU-GM colony growth in agar cultures from bone
marrow cells of melphalan treated mice in the presence of lung
conditioned medium (see legend to Figure 2). Untreated normal
mice grow 60-120 CFU-GM colonies per 1 x 105 bone marrow
cells. (O = group T+M; * =group M.)
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Figure 7 Percentage of splenic B (
treated mice (see legend to Figure 2).
20-35% of spleen cells are SIg+. (O
M.)
GM colonies was persistently low
(group M and T+M) compared t
(P<0.05) (Figure 8). During thir
peripheral blood erythrocytes, leul
not differ between untreated and
shown).
to Figure 2). In untreated declined, These parameters recovered spontaneously by 3-4
were positive.(I =group months after treatment and remained within the normal
range. These results confirm previous studies in normal mice
showing that an intensive course of melphalan causes a
transient cellular immune damage (Harris et al., 1976;
Makinodan et al., 1970; Ehrlich et al., 1983). In contrast,
melphalan-treated plasmacytoma-bearing mice continued to
manifest long lasting and persistent cellular immune
abnormalities up to 1 year after cessation of therapy,
without evidence of tumour recurrence. The most prominent
defect was a marked reduction of splenic T-cell capacity to
__ xd proliferate in response to alloantigens, associated with a
reduced T-cell number and reduced IL-2 production. These
results indicate that the long term T-cell deficiency in
melphalan-treated plasmacytoma cured mice, was not a
consequence of exposure to this cytotoxic agent alone but is
related to previous harbouring of the tumour.
The cause of the T-cell deficiency of the mice cured from
, , , , plasmacytoma is not clear. A number of mechanisms can be
180 240 300 suggested. (a) Plasmacytoma-bearing mice are immuno-
suppressed (Table I); this suppression may persist because of
r inoculation a permanent induction of suppressor function by the tumour
(SIg+) cells in melphalan or the combination of tumour and melphalan. (b) Greater
In untreated normal mice, sensitivity to immune suppression by melphalan in
=group T+M; 0 = group plasmacytoma-bearing mice. Dilution of splenic T-cells by
tumour cells would not account for the observed reduced T-
cell number as no plasmacytoma cells were detected in the
i in both treated groups spleen. Whether indolent and undetectable plasmacytoma
to untreated control mice cells that can modify the immune response are present,
s period the number of remains unanswered.
kocytes and platelets did Although melphalan temporarily suppressed the number
treated mice (data not of B cells, they recovered in both plasmacytoma-bearing and
normal mice. Furthermore, the number of splenic B cells in
group T+M seem to remain higher compared to group M
Immunefunctions and CFU-GM growth in untreated
plasmacytoma bearing mice
Thirty mice with active progressive untreated plasmacytoma
were studied on day 30-45 after tumour inoculation (Table
I). They showed severe impairment of MLR and NK
activity, slight reduction in T-cell number and IL-2
production, normal numbers of NK and B cells and elevated
CFU-GM colony growth.
Discussion
Curative doses of melphalan administered to plasmacytoma-
bearing or to normal mice have short term immuno-
modulatory effects. However, we are not aware of any study
measuring long term effects of this drug on the immune
system of normal compared with plasmacytoma-bearing
mice. In the former, shortly after melphalan administration,
the number and functions of T and NK cells slightly
Table I Immune functions and CFU-GM
colony growth in untreated plasmacytoma
bearing mice
Test % ofcontrol
MLR 20
Thy 1.2+ cells 74
IL-2 production 80
NK activity 20
Asialo GM1 + cells 100
SIg+ cells 100
CFU-GM colonies 140
Parameters were tested in 30 mice between
day 30 and 45 after tumour inoculation. The
figures represent percentage of activity of
untreated control mice assayed on the same
day. For the normal range of activities see
legends to Figures 2-8.
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and untreated mice. The B cells in the tumour bearing group
are normal B cells as evidenced by surface markers studies.
This is an interesting observation, since an increased marrow
B and pre B cell compartment was also found in patients
with acute lymphocytic leukaemia, lymphoma and solid
tumours in remission for more than 2 years after cessation of
therapy (Paolucci et al., 1979; Pearl, 1983).
Previous studies in normal mice demonstrated that the
alkylating agents, melphalan and busulphan, produce
permanent injury to the proliferative capacity of the marrow
haemopoietic stem cells. Decreased marrow CFU-S and
CFU-GM pools (Morley et al., 1975; Hays et al., 1982;
Fried & Adler, 1985) and CFU-S self renewal capacity
(Botnick et al., 1978) was evident even 2 years after
termination therapy. The present results show that one of
the haemopoietic precursors, i.e., the growth of CFU-GM
colonies, is permanently suppressed by melphalan but in
contrast to T-cell number and function, its suppression is
independent of the presence of a previous tumour.
Morley and Blake (1974) have reported that normal mice
surviving the acute toxicity of busulphan administration
show a high rate of late deaths. The mice died from marrow
failure with blood cytopenia or from leukaemia, after a
period of a latent bone marrow injury. In the present study,
the administration of melphalan for a short period resulted
in a slightly reduced survival. Plasmacytoma-bearing mice
cured by the same dose of melphalan had an even greater
mortality rate, the cause of which could not be established in
the present study. Though, in no instance, could we find
plasmacytoma recurrence investigations are needed to
determine if the excess mortality in group T+M was due to
marrow failure, to infections related to the immune
deficiency or to other causes. Previous reports on release of
viruses by MOPC-315 plasmacytoma cells may have
relevance in explaining this observation (Schwarzbard et al.,
1985). However our data support the notion that in animals
cured of plasmacytoma, the late sequelae are not due to the
drugs alone; survival and immune functions may be modified
by the presence of factors related to the cancer in the past.
Clinical experience suggests that myelodysplasia and
secondary acute leukaemia occur more frequently in multiple
myeloma than in other categories of cancer patients receiving
similar drugs (Bergsagel & Pruzanski, 1985; Fisher et al.,
1985). Whether in our model, the immune deficiency in
melphalan-treated plasmacytoma-bearing mice will lead to
more leukaemias than in melphalan treated normal mice,
remains to be established.
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